Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

We recently published a list of Starter Stock Portfolio 12 Safe Stocks to Buy. In this article, we are going to take a look ...

Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%. Investors are beginning to scoff at its expensive price tag, with Eli Lilly trading ...

Financial giants have made a conspicuous bullish move on Eli Lilly ... In the last month, 1 experts released ratings on this stock with an average target price of $1100.0. Unusual Options Activity ...

while Novo Nordisk stock does not. The price of Eli Lilly shares remains above the VWAP [volume-weighted average price], and its RSI [49.12] on the 1-H timeframe is above the neutral zone even ...

pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's... On Monday, Jefferies maintained a confident stance on Eli Lilly (NYSE:LLY) shares, reiterating a Buy rating and a ...

Eli Lilly (LLY ... such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued ...